Karen Moriarty, APRN
Adult Health · Branford, CTNPI 1467666347
Payments from drug & device makers
Across 453 payments — averaging $26.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$3K
- Corcept Therapeutics$1K
- Amgen$920
- Abbott$884
- Boehringer Ingelheim$869
- Lilly USA, LLC$859
- plus $4K from 34 others
What the payments were for
- Consulting fees$1,44012%
- Speaking & faculty fees$5955%
- Food & beverage$9,74483%
- Education$120%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 104 | $2,761 |
| Corcept Therapeutics | 11 | $1,012 |
| Amgen(2 entities) | 30 | $920 |
| Abbott | 28 | $884 |
| Boehringer Ingelheim | 25 | $869 |
| Lilly USA, LLC | 44 | $859 |
| AbbVie | 31 | $456 |
| Insulet Corporation | 22 | $418 |
| AstraZeneca(2 entities) | 21 | $411 |
| Dexcom, Inc. | 14 | $331 |
| Medtronic | 13 | $260 |
| Mannkind Corporation | 8 | $245 |
| Amneal Pharmaceuticals LLC | 10 | $230 |
| Sanofi-aventis U.S. LLC | 11 | $225 |
| Kyowa Kirin, Inc. | 5 | $214 |
| Amarin Pharma, Inc. | 13 | $213 |
| Tandem Diabetes Care, Inc. | 5 | $196 |
| Xeris Pharmaceuticals, Inc. | 8 | $165 |
| Radius Health, Inc. | 7 | $162 |
| Ascendis Pharma Endocrinology Inc | 2 | $123 |
| Acerus Pharmaceuticals Corporation | 5 | $112 |
| IBSA Pharma Inc. | 5 | $99 |
| Lifescan, Inc. | 4 | $82 |
| Clarus Therapeutics Inc. | 3 | $69 |
| Alfasigma USA, Inc. | 3 | $62 |
| Merck | 3 | $55 |
| Zealand Pharma US, Inc. | 3 | $50 |
| Currax Pharmaceuticals LLC | 3 | $47 |
| Neurocrine Biosciences, Inc. | 1 | $31 |
| BETA Bionics, Inc. | 1 | $31 |
| Sequel Med Tech, LLC | 1 | $29 |
| Bayer | 1 | $25 |
| BD | 1 | $24 |
| Sandoz | 1 | $24 |
| Johnson & Johnson | 1 | $18 |
| Recordati_rare_diseases_inc. | 1 | $17 |
| Endo Pharmaceuticals Inc. | 1 | $17 |
| Acella Pharmaceuticals, LLC | 1 | $16 |
| Cequr Corporation | 1 | $15 |
| Amryt Pharma Holdings Ltd | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$11,790 in reported general payments places this provider in the 95th percentile of 418 adult health providers in Connecticut.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 369 | $753,579 |
| JardianceEmpagliflozin | 216 | $332,607 |
| TrulicityDulaglutide | 116 | $214,850 |
| FarxigaDapagliflozin Propanediol | 135 | $173,882 |
| MounjaroTirzepatide | 81 | $161,051 |
| Tresiba Flextouch U-100Insulin Degludec | 134 | $88,062 |
| JanuviaSitagliptin Phosphate | 61 | $84,874 |
| Tresiba Flextouch U-200Insulin Degludec | 72 | $79,157 |
| TymlosAbaloparatide | 23 | $71,277 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 32 | $52,191 |
| RybelsusSemaglutide | 26 | $47,436 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 33 | $46,905 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 26 | $43,504 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 39 | $41,945 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 140 | $28,598 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus, Novolog | $2,761 | $809,860416 claims |
| Lilly USA, LLCTrulicity, Mounjaro, Humalog | $859 | $387,277234 claims |
| Boehringer IngelheimJardiance | $869 | $332,607216 claims |
| AstraZenecaFarxiga | $411 | $173,882135 claims |
| MerckJanuvia | $55 | $84,87461 claims |
| Radius Health, Inc.Tymlos | $162 | $71,27723 claims |
| AbbVieSynthroid, Armour Thyroid | $456 | $13,459113 claims |
| Amneal Pharmaceuticals LLCUnithroid, Levothyroxine Sodium | $230 | $8,234328 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 418 adult health providers in Connecticut.
Other adult health in Branford
- Jillian ReidBranford$11K
- Leah EhleManchester$418K
- Laura MulkaWethersfield$306K
- Gretchen MichaelsonSouth Windsor$169K
- Kimberly RyanWethersfield$74K
- Kathryn JackMeriden$67K
- Lynn RapsilberTorrington$52K
- Genice NelsonFarmington$36K
- Andrea LauterNew London$32K
- Megan CarlucciManchester$28K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.